TPB Stock Forecast & Price Target

Turning Point Brands is viewed favorably because modern oral revenue continues to outpace expectations, with 3Q EBITDA rebounding 21% sequentially and $18.4 mm delivered, suggesting operating momentum is stronger than the market has implied. The company’s outlook is further supported by broad distribution opportunity for FRE and ALP, potential upside from large-chain expansion and lower slot fees, and a second PMTA listing that could eventually lift Stoker’s gross margin by about 200 bps through onshoring. Even with elevated investment spending weighing on valuation, the business appears positioned for sequential growth, a cleaner profitability setup in 2027, and a recurring beat-and-raise profile.

Turning Point Brands is facing a negative setup because its modern oral nicotine business may struggle to sustain initial distribution gains as competition intensifies, shelf space risk rises, and brick-and-mortar expansion of ALP could cannibalize DTC sales. Management’s FY26 guidance of $330M-$350M in gross sales, $260M-$270M in net sales, and $70M-$80M in EBITDA was narrowed due to higher freight costs and delays in onshoring, while estimated EBITDA was cut to $75M from $77M. The outlook is further pressured by the possibility that FRE fails to resonate, slotting fees and investment spending stay elevated, and PMTA approval for nicotine pouch brands never materializes, limiting a margin inflection.